Toxin and Immunotoxin Based Therapeutic Approaches / / edited by Massimo Bortolotti, Letizia Polito, Andrea Bolognesi.
In 1900, Paul Ehrlich, who was studying ricin and abrin at the time, discovered antibodies and paved the way for immunotherapy. After 120 years, Ehrlich's insight into the therapeutic potential of immunotargeting is still a source of inspiration for many scientists. One of the most studied anti...
Saved in:
TeilnehmendeR: | |
---|---|
Place / Publishing House: | Basel : : MDPI - Multidisciplinary Digital Publishing Institute,, 2022. |
Year of Publication: | 2022 |
Language: | English |
Physical Description: | 1 online resource (122 pages) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993562204504498 |
---|---|
ctrlnum |
(CKB)4920000001372300 (NjHacI)994920000001372300 (EXLCZ)994920000001372300 |
collection |
bib_alma |
record_format |
marc |
spelling |
Toxin and Immunotoxin Based Therapeutic Approaches / edited by Massimo Bortolotti, Letizia Polito, Andrea Bolognesi. Basel : MDPI - Multidisciplinary Digital Publishing Institute, 2022. 1 online resource (122 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Description based on online resource; title from PDF title page (MDPI - Multidisciplinary Digital Publishing Institute, viewed February 24, 2023). In 1900, Paul Ehrlich, who was studying ricin and abrin at the time, discovered antibodies and paved the way for immunotherapy. After 120 years, Ehrlich's insight into the therapeutic potential of immunotargeting is still a source of inspiration for many scientists. One of the most studied antibody-based targeting strategies is the carrying of powerful toxins. The generated molecules are immunotoxins, i.e., chimeric proteins obtained by coupling bacterial or plant toxins and antibodies through chemical linking or genetic engineering. Immunotoxins are functionally designed to eliminate the cells responsible for pathological conditions, and they find applications in several fields, ranging from cancer to immunological diseases or pain control. Despite the lack of specificity, even native toxins find clinical application, but the use of unconjugated toxins is limited to loco-regional treatments. A fundamental requirement for the medical application of toxins and their immunoconjugates is in-depth knowledge of their interaction with target cells in terms of binding, uptake, intracellular routing, and substrate specificity. This Special Issue focuses on toxins and immunotoxins that have clinical potential. We hope to give the reader a comprehensive overview of new toxin delivery strategies and toxin-based experimental disease models, both in vitro and in vivo. Clinical medicine. 3-0365-3065-7 Bolognesi, Andrea, editor. Polito, Letizia, editor. Bortolotti, Massimo, editor. |
language |
English |
format |
eBook |
author2 |
Bolognesi, Andrea, Polito, Letizia, Bortolotti, Massimo, |
author_facet |
Bolognesi, Andrea, Polito, Letizia, Bortolotti, Massimo, |
author2_variant |
a b ab l p lp m b mb |
author2_role |
TeilnehmendeR TeilnehmendeR TeilnehmendeR |
title |
Toxin and Immunotoxin Based Therapeutic Approaches / |
spellingShingle |
Toxin and Immunotoxin Based Therapeutic Approaches / |
title_full |
Toxin and Immunotoxin Based Therapeutic Approaches / edited by Massimo Bortolotti, Letizia Polito, Andrea Bolognesi. |
title_fullStr |
Toxin and Immunotoxin Based Therapeutic Approaches / edited by Massimo Bortolotti, Letizia Polito, Andrea Bolognesi. |
title_full_unstemmed |
Toxin and Immunotoxin Based Therapeutic Approaches / edited by Massimo Bortolotti, Letizia Polito, Andrea Bolognesi. |
title_auth |
Toxin and Immunotoxin Based Therapeutic Approaches / |
title_new |
Toxin and Immunotoxin Based Therapeutic Approaches / |
title_sort |
toxin and immunotoxin based therapeutic approaches / |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute, |
publishDate |
2022 |
physical |
1 online resource (122 pages) |
isbn |
3-0365-3065-7 |
callnumber-first |
R - Medicine |
callnumber-subject |
RC - Internal Medicine |
callnumber-label |
RC48 |
callnumber-sort |
RC 248 T695 42022 |
illustrated |
Not Illustrated |
dewey-hundreds |
600 - Technology |
dewey-tens |
610 - Medicine & health |
dewey-ones |
616 - Diseases |
dewey-full |
616 |
dewey-sort |
3616 |
dewey-raw |
616 |
dewey-search |
616 |
work_keys_str_mv |
AT bolognesiandrea toxinandimmunotoxinbasedtherapeuticapproaches AT politoletizia toxinandimmunotoxinbasedtherapeuticapproaches AT bortolottimassimo toxinandimmunotoxinbasedtherapeuticapproaches |
status_str |
n |
ids_txt_mv |
(CKB)4920000001372300 (NjHacI)994920000001372300 (EXLCZ)994920000001372300 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Toxin and Immunotoxin Based Therapeutic Approaches / |
author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField |
_version_ |
1764993888930496512 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02499nam a2200301 i 4500</leader><controlfield tag="001">993562204504498</controlfield><controlfield tag="005">20230225102143.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">230225s2022 sz o 000 0 eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)4920000001372300</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(NjHacI)994920000001372300</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)994920000001372300</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">NjHacI</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">NjHacl</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC48</subfield><subfield code="b">.T695 2022</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">616</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Toxin and Immunotoxin Based Therapeutic Approaches /</subfield><subfield code="c">edited by Massimo Bortolotti, Letizia Polito, Andrea Bolognesi.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Basel :</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute,</subfield><subfield code="c">2022.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (122 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on online resource; title from PDF title page (MDPI - Multidisciplinary Digital Publishing Institute, viewed February 24, 2023).</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In 1900, Paul Ehrlich, who was studying ricin and abrin at the time, discovered antibodies and paved the way for immunotherapy. After 120 years, Ehrlich's insight into the therapeutic potential of immunotargeting is still a source of inspiration for many scientists. One of the most studied antibody-based targeting strategies is the carrying of powerful toxins. The generated molecules are immunotoxins, i.e., chimeric proteins obtained by coupling bacterial or plant toxins and antibodies through chemical linking or genetic engineering. Immunotoxins are functionally designed to eliminate the cells responsible for pathological conditions, and they find applications in several fields, ranging from cancer to immunological diseases or pain control. Despite the lack of specificity, even native toxins find clinical application, but the use of unconjugated toxins is limited to loco-regional treatments. A fundamental requirement for the medical application of toxins and their immunoconjugates is in-depth knowledge of their interaction with target cells in terms of binding, uptake, intracellular routing, and substrate specificity. This Special Issue focuses on toxins and immunotoxins that have clinical potential. We hope to give the reader a comprehensive overview of new toxin delivery strategies and toxin-based experimental disease models, both in vitro and in vivo.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Clinical medicine.</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-3065-7</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bolognesi, Andrea,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Polito, Letizia,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bortolotti, Massimo,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-03-01 01:51:15 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-09-22 08:09:39 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338227780004498&Force_direct=true</subfield><subfield code="Z">5338227780004498</subfield><subfield code="8">5338227780004498</subfield></datafield></record></collection> |